December #192 : ‘Quad’ as Effective as Older Options, Fewer Side Effects - by Benjamin Ryan

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents


The POZ 100: Celebrating Unsung Heroes

The POZ 100: A-C

The POZ 100: D-F

The POZ 100: G-H

The POZ 100: J-L

The POZ 100: M-O

The POZ 100: P-R

The POZ 100: S-T

The POZ 100: V-Z

Positive Networks

From the Editor

Your Song


Letters-December 2013


Fire in the Blood

POZ Planet

Law of Desire

Do Some Men Want to Get AIDS?

Rocky Road

Public Knowledge

First in the Fight

Remembrance of Things Past

That ’80s Show

Say What? Lee Daniels Edition


Remembering J.C. Suares

Care and Treatment

Now Available: New Integrase Inhibitor

‘Quad’ as Effective as Older Options, Fewer Side Effects

Does HIV Make Addiction More Insidious?

TB Preventative Therapy Lowers Deaths by One Third

FDA OKs First Rapid Test for Acute HIV

GMHC Treatment Issues December 2013

Research Notes

Prevention: Malaria Vaccine Shows Promise

Treatment: Soybean Compound May Fight HIV

Cure: Drug-Free Viral Control in Monkeys

Concerns: Lymphoma Survival Unimproved

POZ Survey Says

Your Voice

POZ Heroes

A Mother’s Love

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

December 2013

‘Quad’ as Effective as Older Options, Fewer Side Effects

by Benjamin Ryan

New research shows that the once-daily combination therapy Stribild, also known as the “Quad” because it contains four antiretrovirals (ARVs), is as effective as both Atripla and a Reyataz plus Truvada combination. Researchers recruited 1,408 people with HIV and randomly assigned 701 to receive Stribild, 352 to take Atripla and 355 to take Reyataz plus Truvada.

After 96 weeks of treatment, 84 percent of those on Stribild had an undetectable viral load, compared with 82 percent in both of the other groups. CD4 gains were also similar between the three treatment arms, ranging between 261 and 275 new cells.

Meanwhile, Stribild showed promise in the psychiatric side effects category. Fourteen percent of those taking Atripla reported abnormal dreams, while just 4 percent of those taking Stribild and 1 percent of those on Reyataz plus Truvada did so. Four percent of the Atripla arm reported dizziness, compared with only I percent in the other two groups.

Tony Mills, MD, an HIV doctor in Los Angeles who says he’s “so much more likely” to prescribe Stribild than Atripla, anticipates the older drug will see its blockbuster status fade away. In a recent discussion with top HIV physicians from across the country, he reports: “Everybody across the board said they couldn’t remember the last time they’d written a [new] prescription for Atripla.”

Search: Quad, Stribild, ARVs, antiretrovirals

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.